Diabetic Peripheral Neuropathy
Conditions
Brief summary
A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.
Detailed description
Multi-center, sham-controlled, double-blind, enriched enrollment, randomized withdrawal clinical trial conducted on subjects with bilateral symmetrical diabetic peripheral neuropathy. Eligible subjects will include those between 22 and 80 years of age with Type 1 or Type 2 diabetes having persistent pain, numbness, tingling, or burning in both feet despite treatment. Eligible subjects will receive two active treatment devices (one for each foot, to allow simultaneous treatment) and treat at home, twice daily for 60 days after which they will return to the clinic at Day 61 for a response assessment. Subjects that are determined to be responders at Day 61 (subjects that achieve a 1-point decrease in the average pain score over the last 24 hours using the Numeric Pain Rating Scale (NPRS)) will be randomized 1:1 to either active treatment or inactive sham devices and will continue treating through Day 120. Subjects that are determined to be non-responders at Day 61 will continue treating with the active devices given at enrollment and will return to the clinic at Day 75 and Day 91 for a response assessment. If a subject is determined to be a responder at Day 75, they will be randomized 1:1 to receive either active treatment or inactive sham and will continue treating through Day 120. If a subject is determined to be a responder at Day 91, they will be randomized 1:1 to receive either active treatment or sham and will continue to treat through Day 120. If a subject continues to be a non-responder at Day 91 they will be terminated from the study.
Interventions
Treatment with active Provant Therapy System
Treatment with Inactive (sham) Provant Therapy System
Sponsors
Regenesis Biomedical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sham devices will look identical to active devices. This is a double-blind study.
Intervention model description
Subjects deemed responders after active treatment will be randomized in a 1:1 ratio to either active treatment or a sham device.
Eligibility
Sex/Gender
ALL
Age
22 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subject age is greater than or equal to 22 years and less than 80 years of age. 2. Subject has documented Type 1 or Type 2 diabetes mellitus (receiving insulin, diet controlled, or taking parenteral hypoglycemic agents) 3. Subject is on a stable antidiabetic regimen (medication and/or diet) to control their diabetes for at least 30 days prior to Screening. 4. Subject has an HbA1c \<10% at Screening or within 2 months of Screening. 5. Subject has daily pain attributed to bilateral symmetrical Diabetic Peripheral Neuropathy with numbness, tingling, and/or burning based on clinical judgement for at least 6 months prior to screening. 6. Subject's pain or discomfort from DPN is identifiable. 7. Subject is in pain Phase 2, 3, or 4 as per the Phasing of Neuropathy Scale. 8. Subjects average pain over the last 24 hours is ≥3 based on the 11-point Numeric Pain Rating Scale (NPRS) at the Screening Visit. 9. Subject has adequate lower extremity pulse in both feet and no intermittent claudication. 10. Subject is able to ambulate independently without assistive devices. 11. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol. 12. Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agrees to practice) an effective method of birth control if they are sexually active for the duration of the study (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).
Exclusion criteria
1. Subject is in pain Phase 1 or 5 as per the Phasing of Neuropathy Scale. 2. Subject has an active, open ulcer on the lower extremities. 3. Subject has peripheral vascular disease defined as absence of more than one foot pulse per foot and/or ABI \<0.8 and \>1.4 and/or history of angioplasty or peripheral bypass surgery within 6 months of the Screening Visit. 4. Subject has venous insufficiency as classified by the Venous Insufficiency Classification System of grade C6. 5. Subject has undergone nerve decompression surgery on the lower extremities. 6. Subject has a history of previous kidney, pancreas, cardiac transplantation, or severe renal disease. 7. Subject has been diagnosed with non-diabetic chronic inflammatory neuropathic disease (e.g. end stage renal disease, hepatitis C, chemotherapy induced neuropathy, known connective tissue disease, systemic lupus). 8. Subject has peripheral vascular disease requiring revascularization of lower limb or amputation or evidence of ulcer amputation. 9. Subject has clinically significant cardiovascular disease within 6 months prior to screening (unstable or poorly controlled hypertension, transient ischemic attack, MI, unstable angina, arrhythmia, any heart surgery, stent placement, heart disease). 10. Subject has a history of any uncontrolled medical illness that in the Investigators judgment places the subject at unacceptable risk for receipt of PEMF therapy. 11. Subject requires or anticipates the need for surgery of any type or travel during the treatment period. 12. Subject has a total foot depth (most inferior aspect of the medial malleolus to the plantar aspect of the foot when residing on a treatment pad) of \>8 cm. 13. Subject has received any investigational drug or device within 30 days prior to the Screening Visit or within 6 weeks prior to the Screening Visit for long acting lidocaine injection products. 14. Subject has used systemic corticosteroids within 3 months of the Screening Visit. 15. Subject has a history of malignancy within the past 5 years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area and/or localized in situ carcinoma of the cervix. 16. Subject has a serious psychosocial co-morbidity. 17. Subject has a history of drug or alcohol abuse, as confirmed by urine drug screen, within one year prior to the Screening Visit. 18. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s). 19. Subject is currently pregnant or planning on becoming pregnant prior to Day 121. 20. Subject has previously treated with PROVANT® Therapy System within 60 days on the lower extremity. 21. Subject is unwilling or unable to follow study instructions or comply with the treatment regimen, diary documentation, and study visits. 22. Subject has pain from any other source that can confuse the assessment of the pain associated with DPN. 23. Subject has a clinically significant foot deformity (Charcot's syndrome or club foot). 24. Subject has received nerve blocks for neuropathic pain within 4 weeks of the Screening Visit. 25. Subject has been diagnosed with mononeuropathy. 26. Subject has a skin condition that could alter their sensation. 27. Subject has had a previous surgery to the spine or lower extremity with residual symptoms of pain or difficulty with movement. 28. Subject has moderate or severe arthropathy (RA, OA, Gout) that causes discomfort during casual walking or stair climbing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vibration Perception Threshold (VPT) | Baseline to End of Treatment (Day 121) | A non-invasive test used in quantifying sensation/sensitivity to vibration in evaluating sensory dysfunction associated with diabetic neuropathy |
| Quantitative Sensory Testing (QST) | Baseline to End of Treatment (Day 121) | QST is a noninvasive test used in peripheral nervous system disorders for thermal sensory testing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Intensity (PI) | Collected as patient-reported outcomes on a paper diary and at the Enrollment visit to obtain a baseline value and on Days 61, 75, and 91 | Mean change from Baseline to Day 121, using a validated 11-point Numeric Pain Rating Scale (NPRS) with scores 0-10, where 0 = no pain and 10 = worst possible pain. |
| Brief Pain Inventory (BPI); Question on Pain Right Now. | Change in BPI, pain right now question, from Baseline to Day 121. | The BPI long form will be administered at the Enrollment Visit, Day 30, 61, 91, and end of study visit (Day 121). Results for question #15 on Pain Right Now displayed below. Subject were asked to rate pain right now on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). |
| Brief Fatigue Inventory (BFI) | Change from Baseline to Day 121 in BFI. | A 4-question assessment that assesses the level of fatigue and the impact of the fatigue on daily function over the last 24 hours. BFI is patient reported and collected at the Enrollment Visit, Days 30, 61, 91, and end of study visit (Day 121). A global fatigue score was calculated by averaging all of the values on the questionnaire and results for the change from Baseline to Day 121 are displayed below. The scale ranged from 0 (no fatigue/does not interfere) to 10 (as bad as you can imagine/completely interferes). |
| Nerve Conduction Velocity (NCV) - Velocity | The sural nerve conduction velocity will be recorded at the Enrollment Visit and end of study visit (Day 121). | NC-stat® DPNCheck® will be used to record NCV at Baseline and Day 121. Outcome Measure Data table displays change in NCV from Baseline to Day 121. |
| Hospital Anxiety and Depression Scale (HADS) | Change in Depression and Anxiety from Baseline to Day 121. | A patient reported 14 question assessment that detects the status of depression and anxiety. Subjects completed the assessment at the Enrollment Visit, Days 30, 61, 91, and end of study visit (Day 121). The total score for anxiety and the total score for depression was calculated at Day 121. Low scores represent normal (0-7) while high scores represent abnormal (11-21). |
| Neuro-QoL | Change in each domain from Baseline to Day 121 is displayed below. | A validated set of health-related quality of life measures that are domain specific.Subjects will completed 6 domains: (1) Pain, (2) Lost/Reduced Feeling, (3) Diffuse Sensory Motor Symptoms, (4) Restrictions in Activities of Daily Living, (5) Disruptions in Social Relationships, and (6) Emotional Distress.The short forms were completed by the subject at the Enrollment Visit and end of study visit (Day 121). Each question in the domain was rated on a symptom scale from 1 (never) to 5 (all the time) and a bothersome scale from 1 (none) to 3 (very much). The total score for the domain was calculated by multiplying the symptom score by the bothersome score. The scale range is from 1 to 15 where the minimum (best/least symptomatic) score is 1 and the maximum (worst/most symptomatic) score is 15. |
| Nerve Conduction Velocity (NCV) - Amplitude | The sural nerve conduction amplitude will be recorded at the Enrollment Visit and end of study visit (Day 121). | NC-stat® DPNCheck® will be used to record NCV at Baseline and Day 121. Outcome Measure Data table displays change in NCV from Baseline to Day 121. |
| Patient Global Impression of Change (PGIC) | PGIC results at Day 121 displayed below. | A 7-choice validated categorical scale of overall change in status since initiation of treatment with the study device.PGIC was collected every 7 days in the paper diary, immediately following the morning treatment. Subjects were asked: Since the start of the study, my overall status is? Choices on the scale included: Very much worse, much worse, minimally worse, no change, minimally improved, much improved and very much improved. |
| Skin Perfusion Pressures (SPP) | SPP will be conducted at the Enrollment Visit, Day 61, and end of study visit (Day 121). | The Vasamed Sensilase PAD-IQ will be used to record SPP. This machine measures pressure (in mm Hg) of microcirculation using a laser Doppler sensor. Outcome Measure Data Table below displays change from Baseline to Day 121. |
Countries
United States
Participant flow
Pre-assignment details
A total of 44 subjects were enrolled into the trial and given active Provant Therapy. A total of 7 subjects dropped out of the study prior to being randomized 1:1 active to sham. Since these subjects withdrew from the study prior to assignment to an arm, they are not included in the randomized total of 37 (18 active and 19 sham).
Participants by arm
| Arm | Count |
|---|---|
| Active Group Treatment with active Provant Therapy System
Active Provant Therapy System: Treatment with active Provant Therapy System | 18 |
| Sham Group Treatment with Inactive (sham) Provant Therapy System
Inactive (sham) Provant Therapy System: Treatment with Inactive (sham) Provant Therapy System | 19 |
| Total | 37 |
Baseline characteristics
| Characteristic | Active Group | Total | Sham Group |
|---|---|---|---|
| Age, Continuous | 62.5 years | 62.27 years | 62.05 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 17 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 20 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 5 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 15 Participants | 31 Participants | 16 Participants |
| Region of Enrollment United States | 18 participants | 37 participants | 19 participants |
| Sex: Female, Male Female | 6 Participants | 15 Participants | 9 Participants |
| Sex: Female, Male Male | 12 Participants | 22 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 8 / 44 | 3 / 44 | 2 / 44 |
| other Total, other adverse events | 2 / 44 | 0 / 44 | 0 / 44 |
| serious Total, serious adverse events | 2 / 44 | 0 / 44 | 0 / 44 |
Outcome results
Primary
Quantitative Sensory Testing (QST)
QST is a noninvasive test used in peripheral nervous system disorders for thermal sensory testing.
Time frame: Baseline to End of Treatment (Day 121)
Population: Number analyzed in outcome measure table is less than overall number analyzed due to drop-outs and technical issues with the QST machine.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Active Group | Quantitative Sensory Testing (QST) | Baseline QST, Abnormal Result | 9 Participants |
| Active Group | Quantitative Sensory Testing (QST) | Baseline QST, Normal Result | 6 Participants |
| Active Group | Quantitative Sensory Testing (QST) | Day 121 QST, Abnormal Result | 4 Participants |
| Active Group | Quantitative Sensory Testing (QST) | DAy 121 QST, Normal | 7 Participants |
| Sham Group | Quantitative Sensory Testing (QST) | DAy 121 QST, Normal | 8 Participants |
| Sham Group | Quantitative Sensory Testing (QST) | Baseline QST, Abnormal Result | 8 Participants |
| Sham Group | Quantitative Sensory Testing (QST) | Day 121 QST, Abnormal Result | 4 Participants |
| Sham Group | Quantitative Sensory Testing (QST) | Baseline QST, Normal Result | 6 Participants |
Primary
Vibration Perception Threshold (VPT)
A non-invasive test used in quantifying sensation/sensitivity to vibration in evaluating sensory dysfunction associated with diabetic neuropathy
Time frame: Baseline to End of Treatment (Day 121)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Group | Vibration Perception Threshold (VPT) | Big Toe, change in VPT | 9.26 amplitude in microns | Standard Deviation 32.67 |
| Active Group | Vibration Perception Threshold (VPT) | Plantar Aspect, change in VPT | 9.18 amplitude in microns | Standard Deviation 32.1 |
| Sham Group | Vibration Perception Threshold (VPT) | Big Toe, change in VPT | -3.59 amplitude in microns | Standard Deviation 21.08 |
| Sham Group | Vibration Perception Threshold (VPT) | Plantar Aspect, change in VPT | 1.184 amplitude in microns | Standard Deviation 19.66 |
Secondary
Brief Fatigue Inventory (BFI)
A 4-question assessment that assesses the level of fatigue and the impact of the fatigue on daily function over the last 24 hours. BFI is patient reported and collected at the Enrollment Visit, Days 30, 61, 91, and end of study visit (Day 121). A global fatigue score was calculated by averaging all of the values on the questionnaire and results for the change from Baseline to Day 121 are displayed below. The scale ranged from 0 (no fatigue/does not interfere) to 10 (as bad as you can imagine/completely interferes).
Time frame: Change from Baseline to Day 121 in BFI.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Group | Brief Fatigue Inventory (BFI) | -1.65 units on a scale | Standard Deviation 3.13 |
| Sham Group | Brief Fatigue Inventory (BFI) | -2.3 units on a scale | Standard Deviation 1.98 |
Secondary
Brief Pain Inventory (BPI); Question on Pain Right Now.
The BPI long form will be administered at the Enrollment Visit, Day 30, 61, 91, and end of study visit (Day 121). Results for question #15 on Pain Right Now displayed below. Subject were asked to rate pain right now on a scale from 0 (no pain) to 10 (pain as bad as you can imagine).
Time frame: Change in BPI, pain right now question, from Baseline to Day 121.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Group | Brief Pain Inventory (BPI); Question on Pain Right Now. | -1.65 units on a scale | Standard Deviation 3.02 |
| Sham Group | Brief Pain Inventory (BPI); Question on Pain Right Now. | -1.71 units on a scale | Standard Deviation 2.78 |
Secondary
Hospital Anxiety and Depression Scale (HADS)
A patient reported 14 question assessment that detects the status of depression and anxiety. Subjects completed the assessment at the Enrollment Visit, Days 30, 61, 91, and end of study visit (Day 121). The total score for anxiety and the total score for depression was calculated at Day 121. Low scores represent normal (0-7) while high scores represent abnormal (11-21).
Time frame: Change in Depression and Anxiety from Baseline to Day 121.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Group | Hospital Anxiety and Depression Scale (HADS) | Mean change in depression | -.08 units on a scale | Standard Deviation 2.23 |
| Active Group | Hospital Anxiety and Depression Scale (HADS) | Mean change in anxiety | -.12 units on a scale | Standard Deviation 2.55 |
| Sham Group | Hospital Anxiety and Depression Scale (HADS) | Mean change in depression | -.50 units on a scale | Standard Deviation 2.81 |
| Sham Group | Hospital Anxiety and Depression Scale (HADS) | Mean change in anxiety | -.94 units on a scale | Standard Deviation 4.53 |
Secondary
Nerve Conduction Velocity (NCV) - Amplitude
NC-stat® DPNCheck® will be used to record NCV at Baseline and Day 121. Outcome Measure Data table displays change in NCV from Baseline to Day 121.
Time frame: The sural nerve conduction amplitude will be recorded at the Enrollment Visit and end of study visit (Day 121).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Group | Nerve Conduction Velocity (NCV) - Amplitude | 1.56 meters/second | Standard Deviation 7.68 |
| Sham Group | Nerve Conduction Velocity (NCV) - Amplitude | 4.38 meters/second | Standard Deviation 13.21 |
Secondary
Nerve Conduction Velocity (NCV) - Velocity
NC-stat® DPNCheck® will be used to record NCV at Baseline and Day 121. Outcome Measure Data table displays change in NCV from Baseline to Day 121.
Time frame: The sural nerve conduction velocity will be recorded at the Enrollment Visit and end of study visit (Day 121).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Group | Nerve Conduction Velocity (NCV) - Velocity | 1.69 micro volts | Standard Deviation 15.15 |
| Sham Group | Nerve Conduction Velocity (NCV) - Velocity | -4.23 micro volts | Standard Deviation 13.49 |
Secondary
Neuro-QoL
A validated set of health-related quality of life measures that are domain specific.Subjects will completed 6 domains: (1) Pain, (2) Lost/Reduced Feeling, (3) Diffuse Sensory Motor Symptoms, (4) Restrictions in Activities of Daily Living, (5) Disruptions in Social Relationships, and (6) Emotional Distress.The short forms were completed by the subject at the Enrollment Visit and end of study visit (Day 121). Each question in the domain was rated on a symptom scale from 1 (never) to 5 (all the time) and a bothersome scale from 1 (none) to 3 (very much). The total score for the domain was calculated by multiplying the symptom score by the bothersome score. The scale range is from 1 to 15 where the minimum (best/least symptomatic) score is 1 and the maximum (worst/most symptomatic) score is 15.
Time frame: Change in each domain from Baseline to Day 121 is displayed below.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Group | Neuro-QoL | Change in Domain 1: Pain | -.22 units on a scale | Standard Deviation 0.84 |
| Active Group | Neuro-QoL | Change in Domain 2: Lost/Reducsed Feeling | -.02 units on a scale | Standard Deviation 1.13 |
| Active Group | Neuro-QoL | Change in Domain 3: Diffuse Sensory Motor Symptoms | .06 units on a scale | Standard Deviation 0.52 |
| Active Group | Neuro-QoL | Change in Domain 4: Restrictions in Activities | -.12 units on a scale | Standard Deviation 1.41 |
| Active Group | Neuro-QoL | Change in Domain 5: Disruptions | -.13 units on a scale | Standard Deviation 0.45 |
| Active Group | Neuro-QoL | Change in Domain 6: Emotional Distress | -.25 units on a scale | Standard Deviation 0.52 |
| Sham Group | Neuro-QoL | Change in Domain 5: Disruptions | -.15 units on a scale | Standard Deviation 0.84 |
| Sham Group | Neuro-QoL | Change in Domain 1: Pain | -.54 units on a scale | Standard Deviation 0.9 |
| Sham Group | Neuro-QoL | Change in Domain 4: Restrictions in Activities | -.5 units on a scale | Standard Deviation 1.16 |
| Sham Group | Neuro-QoL | Change in Domain 2: Lost/Reducsed Feeling | -.37 units on a scale | Standard Deviation 0.97 |
| Sham Group | Neuro-QoL | Change in Domain 6: Emotional Distress | -.29 units on a scale | Standard Deviation 1.07 |
| Sham Group | Neuro-QoL | Change in Domain 3: Diffuse Sensory Motor Symptoms | -.35 units on a scale | Standard Deviation 0.8 |
Secondary
Pain Intensity (PI)
Mean change from Baseline to Day 121, using a validated 11-point Numeric Pain Rating Scale (NPRS) with scores 0-10, where 0 = no pain and 10 = worst possible pain.
Time frame: Collected as patient-reported outcomes on a paper diary and at the Enrollment visit to obtain a baseline value and on Days 61, 75, and 91
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Group | Pain Intensity (PI) | -2.69 units on a scale | Standard Deviation 2.47 |
| Sham Group | Pain Intensity (PI) | -2.04 units on a scale | Standard Deviation 2.67 |
Secondary
Patient Global Impression of Change (PGIC)
A 7-choice validated categorical scale of overall change in status since initiation of treatment with the study device.PGIC was collected every 7 days in the paper diary, immediately following the morning treatment. Subjects were asked: Since the start of the study, my overall status is? Choices on the scale included: Very much worse, much worse, minimally worse, no change, minimally improved, much improved and very much improved.
Time frame: PGIC results at Day 121 displayed below.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Active Group | Patient Global Impression of Change (PGIC) | Much Worse | 1 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Very Improved | 0 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Worse | 5 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Very Much Improved | 0 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Very Much Worse | 1 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | No Change | 2 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Improved | 1 Participants |
| Active Group | Patient Global Impression of Change (PGIC) | Not Reported | 8 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Much Worse | 2 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Not Reported | 5 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Very Much Worse | 1 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Worse | 1 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Improved | 2 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Very Improved | 1 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | Very Much Improved | 3 Participants |
| Sham Group | Patient Global Impression of Change (PGIC) | No Change | 4 Participants |
Secondary
Skin Perfusion Pressures (SPP)
The Vasamed Sensilase PAD-IQ will be used to record SPP. This machine measures pressure (in mm Hg) of microcirculation using a laser Doppler sensor. Outcome Measure Data Table below displays change from Baseline to Day 121.
Time frame: SPP will be conducted at the Enrollment Visit, Day 61, and end of study visit (Day 121).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Group | Skin Perfusion Pressures (SPP) | Change in Dorsal SPP | .35 mmHg | Standard Deviation 34.54 |
| Active Group | Skin Perfusion Pressures (SPP) | Change in Medial Plantar SPP | -12.11 mmHg | Standard Deviation 32.98 |
| Sham Group | Skin Perfusion Pressures (SPP) | Change in Dorsal SPP | 3.07 mmHg | Standard Deviation 40.16 |
| Sham Group | Skin Perfusion Pressures (SPP) | Change in Medial Plantar SPP | -2.06 mmHg | Standard Deviation 32.38 |